Monolisa anti hbs plus

Manufactured by Bio-Rad

Sourced in France

Monolisa Anti-HBs Plus is a laboratory diagnostic kit that quantitatively detects the presence of antibodies to the hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The kit utilizes an enzyme-linked immunosorbent assay (ELISA) technique to determine the anti-HBs levels in the samples.

Automatically generated - may contain errors

Lab products found in correlation

Monolisa anti hbc plus, by Bio-Rad (6 mentions) Monolisa hbsag ultra, by Bio-Rad (2 mentions) Anti hbc plus, by Bio-Rad (2 mentions) Realtime hbv assay, by Abbott (1 mentions) Monolisa hbsag ultra kit, by Bio-Rad (1 mentions) Clariostar reader, by BMG Labtech (1 mentions) Monolisa hbeag ab plus kit, by Bio-Rad (1 mentions) M2000rt, by Abbott (1 mentions) Hbsag ultra, by Bio-Rad (1 mentions) Cobas ampliprep taqman hbv test, by Roche (1 mentions)

Spelling variants of this product

Anti-HBs plus (3 citations) Monolisa Anti-HBs PLUS ELISA kit (3 citations) Monolisa Anti-HBs Plus assay (2 citations)

9 protocols using monolisa anti hbs plus

Monitoring HBV Exposure in Infants

Check if the same lab product or an alternative is used in the 5 most similar protocols

HBV infection status at 6 months of age was determined with the Monolisa HBsAg Ultra kit (Bio-Rad). If the results were positive, plasma HBV DNA levels were measured at all visits by a polymerase-chain-reaction assay (RealTime HBV assay, Abbott Molecular). The level of antibody to HBsAg was measured at 2, 4, and 6 months with the Monolisa Anti-HBs Plus (Bio-Rad).
Women with an elevated alanine aminotransferase level (>60 IU per liter) at any trial visit had their level tested again within 2 weeks. If an elevation after 2 months post partum was confirmed, the reintroduction of the double-blind trial regimen was considered. Serious adverse events²⁰ and signs and symptoms that were graded, according to the Division of AIDS tables,²¹ as being severe (grade 3) or potentially life-threatening (grade 4) were coded according to the Medical Dictionary for Regulatory Activities, version 19.0.^{22 (link)}

Jourdain G., Ngo-Giang-Huong N., Harrison L., Decker L., Khamduang W., Tierney C., Salvadori N., Cressey T.R., Sirirungsi W., Achalapong J., Yuthavisuthi P., Kanjanavikai P., Ayudhaya O.P., Siriwachirachai T., Prommas S., Sabsanong P., Limtrakul A., Varadisai S., Putiyanun C., Suriyachai P., Liampongsabuddhi P., Sangsawang S., Matanasarawut W., Buranabanjasatean S., Puernngooluerm P., Bowonwatanuwong C., Puthanakit T., Klinbuayaem V., Thongsawat S., Thanprasertsuk S., Siberry G.K., Watts D.H., Chakhtoura N., Murphy T.V., Nelson N.P., Chung R.T., Pol S, & Chotivanich N. (2018). Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. The New England journal of medicine, 378(10), 911-923.

+ Open protocol

+ Expand

Serological Markers for Hepatitis B

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-HBc and anti-HBs were detected using the Monolisa Anti-HBc PLUS and the Monolisa Anti-HBs PLUS kits (Bio-Rad, Feldkirchen, Germany), respectively. Optical density was measured on a CLARIOstar reader (BMG Labtech, Ortenberg, Germany). Positivity for anti-HBs was defined as an anti-HBs level ≥ 10 mIU/mL. HBsAg was detected by HBsAg one version ULTRA ELISA (DIA.PRO Milano, Italy), which has a diagnostic specificity of 99.5% and analytical sensitivity < 0.1 WHO IU/mL. This was performed following the manufacturer’s instructions.

Hoan N.X., Hoechel M., Tomazatos A., Anh C.X., Pallerla S.R., Linh L.T., Binh M.T., Sy B.T., Toan N.L., Wedemeyer H., Bock C.T., Kremsner P.G., Meyer C.G., Song L.H, & Velavan T.P. (2021). Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis. Viruses, 13(2), 346.

+ Open protocol

+ Expand

Seroprevalence of Viral Hepatitis in a Community

Check if the same lab product or an alternative is used in the 5 most similar protocols

A structured questionnaire was administered by face-to-face interview during house visits to collect sociodemographic, cultural (behavioral), and relevant clinical data. Blood samples (5 mL) were collected from each of the study participants. Sera were separated and stored at −70°C until screening for HBV seromarkers (HBsAg, anti-HBc, and anti-HBs), HBV DNA, and anti-HCV. Screening for seromarkers HBsAg and anti-HCV was undertaken using HbsAg and anti-HCV ELISA kits (Wantai Biological) as per manufacturer instructions. Sensitivity and specificity of the HBsAg kit were 100% and 99.4% and for the anti-HCV kit 99% and 97%, respectively. Anti-HBc and anti-HBs screening tests were also performed using ELISA kits (Monolisa anti-HBc Plus, Monolisa anti-HBs Plus, Bio-Rad). Reactive samples were retested twice more and considered reactive if at least one of the two repetitions also gave a positive result. Samples found positive on HBsAg ELISA assays were further tested using quantitative PCR assays for detection and quantification of viral nucleic acid.

Beykaso G., Mulu A., Giday M., Berhe N., Selamu M., Mihret A, & Teklehaymanot T. (2021). Burden and Transmission Risks of Viral Hepatitis in Southern Ethiopia: Evidence Needed for Prevention and Control Measures. Risk Management and Healthcare Policy, 14, 4843-4852.

+ Open protocol

+ Expand

Hepatitis B Screening in Botswana

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study screened 300 samples, which were available in storage (sample size was calculated based on the latest HBV/HIV prevalence in Botswana reported in literature [5 (link), 25 ]). All samples were screened for HBsAg using the Murex HBsAg version 3 kit (Murex Biotech, Dartford, UK) according to the manufacturer's instructions. Samples positive for HBsAg were then screened for HBeAg using the Monolisa HBeAg-Ab PLUS kit (Bio-Rad, Hercules, CA). Both HBsAg and HBeAg losses were evaluated at 6, 12, 18, and 24 months. Hepatitis B core antibody (HBcAb) and hepatitis surface antibody (HBsAb) were evaluated at baseline using Monolisa Anti-HBC PLUS (Bio-Rad, Marnes-la-Coquette, Paris, France) and Monolisa Anti-HBS PLUS (Bio-Rad, Marnes-la-Coquette, Paris, France) enzyme-linked immunosorbent assay kits according to the manufacturer's instructions, respectively.

Anderson M., Gaseitsiwe S., Moyo S., Thami K.P., Mohammed T., Setlhare D., Sebunya T.K., Powell E.A., Makhema J., Blackard J.T., Marlink R., Essex M, & Musonda R.M. (2016). Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana. Open Forum Infectious Diseases, 3(3), ofw140.

+ Open protocol

+ Expand

Hepatitis B Serological Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the laboratory, 10 ml blood was collected in sterile anticoagulated tube, plasma was separated, labelled and stored at -20°C by medical technologists until transferred to Haramaya University. The plasma samples were screened and interpreted for HBsAg, ant-HBc and ant-HBs using ELISA (Monolisa HBsAg ULTRA, Monolisa Anti-HBc PLUS, Monolisa Anti-HBs PLUS, BIORAD, France) in the Medical Laboratory Science Department, College of Health and Medical Sciences, Haramaya University, following the manufacturer’s instruction.

Ayana D.A., Mulu A., Mihret A., Seyoum B., Aseffa A, & Howe R. (2019). Hepatitis B virus seromarkers among HIV infected adults on ART: An unmet need for HBV screening in eastern Ethiopia. PLoS ONE, 14(12), e0226922.

+ Open protocol

+ Expand

Hepatitis B Serological Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols

HBsAg, anti-HBc and anti-HBs screenings were performed using the Monolisa HBsAg ULTRA, Monolisa Anti-HBcPlus, and Monolisa Anti-HBs Plus kits (Bio-Rad, Marnes-La-Coquette-France), respectively, as described previously [18 (link)]. All the tests were conducted according to the manufacturer’s instructions.

Bivigou-Mboumba B., Amougou-Atsama M., Zoa-Assoumou S., M’boyis Kamdem H., Nzengui-Nzengui G.F., Ndojyi-Mbiguino A., Njouom R, & François-Souquière S. (2018). Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence. PLoS ONE, 13(1), e0190592.

+ Open protocol

+ Expand

Quantitative HBV DNA Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Standard ELISA procedures were followed to detect HBV seromarkers using BIORAD kits (Monolisa HBsAg ULTRA, Monolisa Anti-HBc PLUS, Monolisa Anti-HBs PLUS, BIORAD, France). DNA extraction, amplification and detection were conducted from 200 μl plasma using ABBOTT m2000sp and m2000rt System ABBOTT RealTime PCR (Abbott Molecular Inc.). The target sequence for the Abbott RealTime HBV assay is in the Surface gene in the HBV genome. This region is specific for HBV and is highly conserved. The primers are designed to hybridize to this region with the fewest possible mismatches among HBV genotypes A through H. Target region is upstream of all Tyrosine-methionine aspartate-aspartate (YMDD), HBsAg, and drug resistant mutants. The amplification cycle at which fluorescent signal is detected by the Abbott m2000rt is inversely proportional to the log of the HBV DNA concentration present in the original sample³⁹. In order to check for consistency, 10% of the samples were retested.

Ayana D.A., Mulu A., Mihret A., Seyoum B., Aseffa A, & Howe R. (2020). Occult Hepatitis B virus infection among HIV negative and positive isolated anti-HBc individuals in eastern Ethiopia. Scientific Reports, 10, 22182.

+ Open protocol

+ Expand

Detecting Occult Hepatitis B Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two hundred seventy-two plasma samples from individuals who were previously determined to be HBsAg negative [21 ] were tested for HBV DNA using the COBAS AmpliPrep/TaqMan HBV Test, version 2.0 (Roche Diagnostic, Mannheim, Germany). Quantitative levels were recorded when ≥20 IU/mL, while samples with HBV DNA that were detectable but below this quantitative threshold were reported as <20 IU/mL. Antibody screening for hepatitis B core antibody (Monolisa Anti-HBC PLUS, Biorad, France) and hepatitis B surface antibody (Monolisa Anti-HBS PLUS, Biorad, France) was performed in triplicate per the manufacturer’s instructions. Individuals with OBI at baseline and follow-up plasma samples obtained 1 year after initiation of HAART were evaluated for HBV DNA at 1 year using the COBAS AmpliPrep/TaqMan system, version 2.0.

Ryan K., Anderson M., Gyurova I., Ambroggio L., Moyo S., Sebunya T., Makhema J., Marlink R., Essex M., Musonda R., Gaseitsiwe S, & Blackard J.T. (2017). High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infectious Diseases, 4(4), ofx195.

+ Open protocol

+ Expand

Hepatitis B Serological Markers Evaluation

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The serological markers of HBV tested were HBsAg, antibody to HBsAg (anti-HBs), and total immunoglobulin IgM and IgG antibodies to hepatitis B core antigen (anti-HBc). A positive HBsAg result signifies current HBV infection, either acute or chronic. Presence of anti-HBc indicates the evidence of current, recent, or past infection, hereafter referred to as ‘exposure’. Anti-HBs is produced in response to HBsAg and confer immunity to re-infection and its presence indicates immunity to HBV infection following an infection or successful immunization with hepatitis B vaccine [17 (link)].
Serum samples were tested for HBsAg, anti-HBs, and anti-HBc using commercially available immunoassays (Monolisa HBsAg Ultra—sensitivity 0.08 ng/mL, Monolisa Anti-HBs Plus, and anti-HBc plus, respectively; Biorad Laboratories, France) according to the manufacturer’s instruction. Anti-HBs level ≥ 10 IU/l was considered positive [18 (link), 19 (link)].

Wijayadi T., Sjahril R., T.u.r.y.a.d.i., Ie S.I., Wahyuni R., Pattelongi I., Massi M.N., Yusuf I, & Muljono D.H. (2018). Seroepidemiology of HBV infection among health-care workers in South Sulawesi, Indonesia. BMC Infectious Diseases, 18, 279.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!